FierceBiotechOriginal article
{"a":[{"_":"Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’","$":{"href":"/biotech/boehringer-benches-phase-1-study-safety-event","hreflang":"en"}}]}
Phase 1negativeNegative
AI Analysis
Summary
Boehringer Ingelheim has suspended a Phase 1 trial of an investigational small molecule drug due to a safety event. The company has not disclosed details about the nature of the incident.
Clinical Trial Data
Phase
1
Outcome Details
Phase 1 trial suspended due to safety event
Importance:6/10
Sentiment:
-0.70
safetytrial suspensionphase 1investigational drug
Read the original article
Published by FierceBiotech on August 20, 2026 3:10 PM
